C. Pater

A faster-acting and more potent form of tissue plasminogen activator.

D. Botstein, B. Keyt, H. Nguyen, 1994, Proceedings of the National Academy of Sciences of the United States of America.

A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent.

R. Kelley, M. O'Connell, S. Bunting, 1997, Blood.

Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group.

C. Pater, K. Nikus, A. Tisell, 1999, American Heart Journal.

Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form

S. Bunting, M. Beresini, K. Robarge, 1998, Thrombosis and Haemostasis.

A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen

B. Keyt, F. Wurm, N. Paoni, 1993, Thrombosis and Haemostasis.

Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5.

P. Campochiaro, S. Kachi, Kris Jones, 2006, Virology.